Pharmacogenomics Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacogenomics, including details on pharmacology, designer drugs, customized medicines.

Volume 2 (2006), Issue 3 (March)

1. Pharmacogenetics in clinical practice: considerations for testing.
   Expert Rev Mol Diagn, 6(2): 193-205. [Abstract] [Full-text]
2. Clinical genomics data standards for pharmacogenetics and pharmacogenomics.
   Pharmacogenomics, 7(2): 247-53. [Abstract] [Full-text]
3. Teaching and practicing pharmacogenomics: a complex matter.
   Pharmacogenomics, 7(2): 243-6. [Abstract] [Full-text]
4. Pharmacogenomic data sample collection and storage: ethical issues and policy approaches.
   Pharmacogenomics, 7(2): 219-26. [Abstract] [Full-text]
5. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies.
   Pharmacogenomics, 7(2): 187-202. [Abstract] [Full-text]
6. Development of a toxicogenomics in vitro assay for the efficient characterization of compounds.
   Pharmacogenomics, 7(2): 177-86. [Abstract] [Full-text]
7. Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms.
   Clin Chem Lab Med, 44(3): 285-7. [Abstract] [Full-text]
8. Drugs and double binds: racial identification and pharmacogenomics in a system of binary race logic.
   Health Commun, 19(1): 61-73. [Abstract] [Full-text]
9. The promise of personalized medicine: a conversation with Michael Svinte. Interview by Michael Millenson.
   Health Aff (Millwood), 25(2): w54-60. [Abstract] [Full-text]
10. dbZach: A MIAME-compliant toxicogenomic supportive relational database.
    Toxicol Sci, 90(2): 558-68. [Abstract] [Full-text]
11. Role of pharmacogenetics in irinotecan therapy.
    Cancer Lett, 234(1): 90-106. [Abstract] [Full-text]
12. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster.
    Pharmacogenet Genomics, 16(4): 287-96. [Abstract] [Full-text]
13. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics.
    Pharmacogenet Genomics, 16(4): 265-77. [Abstract] [Full-text]
14. Dictyostelium discoideum to human cells: pharmacogenetic studies demonstrate a role for sphingolipids in chemoresistance.
    Biochim Biophys Acta, 1760(3): 301-9. [Abstract] [Full-text]
15. Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: design and application.
    Bioinformatics, 22(7): 874-82. [Abstract] [Full-text]
16. Cytochrome P450 pharmacogenetics and cancer.
    Oncogene, 25(11): 1679-91. [Abstract] [Full-text]
17. Pharmacogenetics of human cytosolic sulfotransferases.
    Oncogene, 25(11): 1673-8. [Abstract] [Full-text]
18. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
    Oncogene, 25(11): 1659-72. [Abstract] [Full-text]
19. Utilization of a toxicogenomic biomarker for evaluation of chemical-induced glutathione deficiency in rat livers across the GeneChip data of different generations.
    Toxicol Lett, 163(2): 161-9. [Abstract] [Full-text]
20. Race and ethnicity in the era of emerging pharmacogenomics.
    J Clin Pharmacol, 46(4): 405-7. [Abstract] [Full-text]
21. What race and ethnicity measure in pharmacologic research.
    J Clin Pharmacol, 46(4): 401-4. [Abstract] [Full-text]

© 2005-2008 Pharmacogenomics Research Today. All Rights Reserved.